{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:53:55Z","timestamp":1794048835441,"version":"4.8.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.ijantimicag.2019.10.017","type":"journal-article","created":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T12:10:15Z","timestamp":1572955815000},"page":"105836","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Survival benefit associated with clarithromycin in severe community-acquired pneumonia: A matched comparator study"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9585-517X","authenticated-orcid":false,"given":"Evdoxia","family":"Kyriazopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Sinapidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stamatios","family":"Halvatzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Velissaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Alexiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilios","family":"Kosmas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Evangelia","family":"Adami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miltiades","family":"Kyprianou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Kyprianou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aggelos","family":"Stefos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9979-1495","authenticated-orcid":false,"given":"Malvina","family":"Lada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantelis","family":"Koutoukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Pavlaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kyriakoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Makina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalambos","family":"Gogos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Niederman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4713-3911","authenticated-orcid":false,"given":"Evangelos J.","family":"Giamarellos-Bourboulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2019.10.017_bib0001","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s10096-005-1295-9","article-title":"Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone","volume":"24","author":"Garc\u00eda V\u00e1zquez","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.10.017_bib0002","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1128\/AAC.00006-07","article-title":"Comparison of \u03b2-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized veterans affairs patients with community-acquired pneumonia","volume":"51","author":"Lodise","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.10.017_bib0003","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1086\/367541","article-title":"Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia","volume":"36","author":"Mart\u00ednez","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.10.017_bib0004","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1378\/chest.06-1426","article-title":"Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones","volume":"131","author":"Metersky","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2019.10.017_bib0005","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1183\/09031936.00054108","article-title":"Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia","volume":"33","author":"Restrepo","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2019.10.017_bib0006","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s00134-009-1730-y","article-title":"Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia","volume":"36","author":"Martin-Loeches","year":"2010","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2019.10.017_bib0007","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1086\/529439","article-title":"Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia","volume":"46","author":"Giamarellos-Bourboulis","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.10.017_bib0008","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/jac\/dkt475","article-title":"Effect of clarithromycin in patients with suspected Gram-negative sepsis: results of a randomized controlled trial","volume":"69","author":"Giamarellos-Bourboulis","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.10.017_bib0009","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2019.10.017_bib0010","first-page":"864","article-title":"Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis","volume":"20","year":"1995","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2019.10.017_bib0011","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1164\/rccm.200512-1922OC","article-title":"Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial","volume":"174","author":"Christ-Crain","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2019.10.017_bib0012","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.cmi.2016.11.003","article-title":"Validation of the new sepsis-3 definitions: proposal for improvement in early risk identification","volume":"23","author":"Giamarellos-Bourboulis","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2019.10.017_bib0013","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.cmi.2016.01.021","article-title":"Improving outcomes of severe infections by multidrug-resistant pathogens with polyclonal IgM-enriched immunoglobulins","volume":"22","author":"Giamarellos-Bourboulis","year":"2016","journal-title":"Clin Microb Infect"},{"key":"10.1016\/j.ijantimicag.2019.10.017_bib0014","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/jac\/dku033","article-title":"\u03b2-Lactam\/macrolide dual therapy versus \u03b2-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis","volume":"69","author":"Nie","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.10.017_bib0015","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/resp.12835","article-title":"Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: a systematic review and meta-analysis","volume":"21","author":"Horita","year":"2016","journal-title":"Respirology"},{"key":"10.1016\/j.ijantimicag.2019.10.017_bib0016","first-page":"1043","article-title":"Impact of macrolide therapy in critically ill patients with acute respiratory failure: a desirability of outcome ranking analysis to investigate the OUTCOMEREA database","volume":"45","author":"Pons","year":"2019","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2019.10.017_bib0017","article-title":"Predictors of severe sepsis among patients hospitalized for community-acquired pneumonia","volume":"11","author":"Montull","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2019.10.017_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2016.03.015","article-title":"Declining mortality among hospitalized patients with community-acquired pneumonia","volume":"22","author":"Simonetti","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2019.10.017_bib0019","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1136\/thoraxjnl-2015-207688","article-title":"Increased burden of community-acquired pneumonia leading to hospitalization","volume":"71","author":"Quan","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.ijantimicag.2019.10.017_bib0020","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1500245","article-title":"Community-acquired pneumonia requiring hospitalization among US adults","volume":"373","author":"Jain","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2019.10.017_bib0021","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1128\/AAC.02974-15","article-title":"Clarithromycin leads to long-term survival and cost benefit in ventilator-associated pneumonia and sepsis","volume":"60","author":"Tsaganos","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.10.017_bib0022","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1128\/AAC.05798-11","article-title":"Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by Gram-negative bacteria: results from a randomized clinical study","volume":"56","author":"Spyridaki","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.10.017_bib0023","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/nri3552","article-title":"Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy","volume":"13","author":"Hotchkiss","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ijantimicag.2019.10.017_bib0024","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1001\/jamainternmed.2014.4887","article-title":"\u03b2-Lactam monotherapy vs \u03b2-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial","volume":"174","author":"Garin","year":"2016","journal-title":"JAMA Intern Med"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919302973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919302973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:33:14Z","timestamp":1760376794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857919302973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0924857919302973"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.10.017","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival benefit associated with clarithromycin in severe community-acquired pneumonia: A matched comparator study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105836"}}